The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HRTX | -58.31% | -94.09% | -43.21% | -100% |
| S&P | +17.78% | +74.31% | +11.75% | +1,931% |
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
These two biopharma stocks could be poised for a major growth spurt.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $40.59M | -0.5% |
| Gross Profit | $29.47M | -3.5% |
| Gross Margin | 72.61% | -2.3% |
| Market Cap | $238.37M | 2.4% |
| Market Cap / Employee | $1.86M | 0.0% |
| Employees | 128 | 4.9% |
| Net Income | -$2,954.00K | -180.6% |
| EBITDA | $575.00K | -87.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $28.65M | 11.0% |
| Accounts Receivable | $89.59M | 13.6% |
| Inventory | 92.7 | 74.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $140.64M | -19.5% |
| Short Term Debt | $0.00K | -100.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.47% | 1.5% |
| Return On Invested Capital | -75.97% | 7.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,184.00K | 26.0% |
| Operating Free Cash Flow | -$9,184.00K | 22.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -9.95 | -11.09 | -7.08 | 33.93 | -684.88% |
| Price to Sales | 2.92 | 2.13 | 1.38 | 1.58 | -2.83% |
| Price to Tangible Book Value | -9.95 | -11.09 | -7.08 | 33.93 | -684.88% |
| Enterprise Value to EBITDA | 151.09 | -550.76 | -96.75 | 590.43 | 695.61% |
| Total Debt | $177.26M | $176.74M | $140.44M | $140.64M | -20.88% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
